Nimbus Therapeutics, Westwood & Wilshire Client, Announces $105 Million Private Financing

Nimbus Therapeutics, a biotech designing selective small molecule compounds via its structure-based drug discovery engine, has just announced the closing of a very successful $105 Million private financing round. BVF Partners L.P. led the round, while a large alternative asset manager joined as a new investor, and existing investors threw their hats in the ring as well, including RA Capital Management, Atlas Ventures, Access Biotechnology, and others.

Westwood & Wilshire is currently engaged in two searches for Nimbus, Chief Medical Officer and SVP of Non-Clinical Development. With this round of financing going to funding the advancement of the pipeline, including multiple clinical programs, it’s an exciting time for development at Nimbus.

“Nimbus’ pipeline is positioned to deliver multiple clinical readouts over the next 18 months that have the promise to help transform patients’ lives,” Bruce Booth, co-founder and Chairman of the Board of Nimbus, told BusinessWire. “We are fortunate to have the support of many new investors joining Nimbus, and we welcome Sam Huang from BVF to the Board.”

Between this round of financing and TYK2, Nimbus’ lead asset, a novel allosteric inhibitor, continuing to show compelling data, the company is poised to rocket forward in the next few years. Westwood & Wilshire is thrilled to be helping finding leaders at Nimbus.